Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley R Riddell

Showing results (131-140 of 177) with videos related to

Pageof 18
Sort By:
Transplantation and Cellular Therapy|March 15, 2022
Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple MyelomaSrirama Josyula, Margot J Pont, Sayan Dasgupta, et al.
Blood|April 15, 2017
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsRebecca A Gardner, Olivia Finney, Colleen Annesley, et al.
Journal for Immunotherapy of Cancer|February 7, 2024
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicityTamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, et al.
EMBO Molecular Medicine|September 7, 2022
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activityGökhan Güner, Marlene Aßfalg, Kai Zhao, et al.
Blood|September 24, 2008
HapMap scanning of novel human minor histocompatibility antigensMichi Kamei, Yasuhito Nannya, Hiroki Torikai, et al.
Haematologica|July 2, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphomaValentín Ortiz-Maldonado, Emily C Liang, Jennifer J Huang, et al.
Blood|August 13, 2010
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptorMichael Hudecek, Thomas M Schmitt, Sivasubramanian Baskar, et al.
Blood|February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBrian G Till, Michael C Jensen, Jinjuan Wang, et al.
Nature Structural & Molecular Biology|March 24, 2020
Engineering and functionalization of large circular tandem repeat protein nanoparticlesColin E Correnti, Jazmine P Hallinan, Lindsey A Doyle, et al.
Blood Advances|September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.
Pageof 18

Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
Transplantation and Cellular Therapy|March 15, 2022
Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple MyelomaSrirama Josyula, Margot J Pont, Sayan Dasgupta, et al.
Blood|April 15, 2017
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsRebecca A Gardner, Olivia Finney, Colleen Annesley, et al.
Journal for Immunotherapy of Cancer|February 7, 2024
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicityTamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, et al.
EMBO Molecular Medicine|September 7, 2022
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activityGökhan Güner, Marlene Aßfalg, Kai Zhao, et al.
Blood|September 24, 2008
HapMap scanning of novel human minor histocompatibility antigensMichi Kamei, Yasuhito Nannya, Hiroki Torikai, et al.
Haematologica|July 2, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphomaValentín Ortiz-Maldonado, Emily C Liang, Jennifer J Huang, et al.
Blood|August 13, 2010
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptorMichael Hudecek, Thomas M Schmitt, Sivasubramanian Baskar, et al.
Blood|February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBrian G Till, Michael C Jensen, Jinjuan Wang, et al.
Nature Structural & Molecular Biology|March 24, 2020
Engineering and functionalization of large circular tandem repeat protein nanoparticlesColin E Correnti, Jazmine P Hallinan, Lindsey A Doyle, et al.
Blood Advances|September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.
Pageof 18